We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Aegon N V | BIT:AGN | Italy | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
From May 2019 to May 2024
A journal advertisement for Allergan Inc.'s (AGN) acne cream, Aczone, overstates the medicine's effectiveness and omits key safety information, the U.S. Food and Drug Administration said.
The ad completely misrepresents the results of a study by claiming it shows the medicine "Works fast 24% reduction in inflammatory lesions at 2 weeks," according to the wording of a letter the FDA sent the company on Monday. The agency posted the letter on its Web site Friday.
"This claim is a complete misrepresentation of the results" of a study involving Aczone, the FDA said. Aczone is a topical gel used to treat mild to moderate acne.
The FDA said the ad, which ran in unidentified medical journals, clearly claims the product has a substantial effect on acne after two weeks of treatment, while studies show it has only a slight benefit when compared to a placebo.
The ad in question hasn't been running since May, said Caroline Van Hove. Hove said Allergan is working with the FDA to address all of the agency's concerns.
-By Jared A. Favole, Dow Jones Newswires; 202-862-9207; jared.favole@dowjones.com
1 Year Aegon N V Chart |
1 Month Aegon N V Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
